Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-DowngradedPositive News SentimentPositive NewsNASDAQ:VRNA Verona Pharma PLC American Depositary Share (VRNA) Stock Price, News & Analysis $105.80 +0.02 (+0.01%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verona Pharma PLC American Depositary Share Stock (NASDAQ:VRNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VRNA alerts:Sign Up Key Stats Today's Range$105.71▼$105.8150-Day Range$86.86▼$105.8052-Week Range$24.50▼$105.85Volume289,934 shsAverage Volume2.23 million shsMarket Capitalization$9.15 billionP/E RatioN/ADividend YieldN/APrice Target$109.00Consensus RatingHold Company Overview Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Read More Verona Pharma PLC American Depositary Share Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreVRNA MarketRank™: Verona Pharma PLC American Depositary Share scored higher than 50% of companies evaluated by MarketBeat, and ranked 572nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingVerona Pharma PLC American Depositary Share has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 12 hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma PLC American Depositary Share has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verona Pharma PLC American Depositary Share's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verona Pharma PLC American Depositary Share are expected to grow in the coming year, from ($1.95) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma PLC American Depositary Share is -106.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma PLC American Depositary Share is -106.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma PLC American Depositary Share has a P/B Ratio of 32.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verona Pharma PLC American Depositary Share's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.05% of the float of Verona Pharma PLC American Depositary Share has been sold short.Short Interest Ratio / Days to CoverVerona Pharma PLC American Depositary Share has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verona Pharma PLC American Depositary Share has recently decreased by 39.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerona Pharma PLC American Depositary Share does not currently pay a dividend.Dividend GrowthVerona Pharma PLC American Depositary Share does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.05% of the float of Verona Pharma PLC American Depositary Share has been sold short.Short Interest Ratio / Days to CoverVerona Pharma PLC American Depositary Share has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verona Pharma PLC American Depositary Share has recently decreased by 39.16%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment1.64 News SentimentVerona Pharma PLC American Depositary Share has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Verona Pharma PLC American Depositary Share this week, compared to 9 articles on an average week.Search InterestOnly 4 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verona Pharma PLC American Depositary Share to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verona Pharma PLC American Depositary Share insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,983,983.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma PLC American Depositary Share is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma PLC American Depositary Share is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma PLC American Depositary Share's insider trading history. Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma PLC American Depositary Share and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRNA Stock News HeadlinesJames Aloysius Brady Sells 824 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockAugust 6, 2025 | insidertrades.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives $109.00 Average Target Price from AnalystsAugust 27 at 2:55 AM | americanbankingnews.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 28 at 2:00 AM | American Alternative (Ad)Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Short Interest Down 39.2% in JulyAugust 20, 2025 | americanbankingnews.comMerck’s $10B Verona Deal: A High-Stakes Play in Respiratory CareJuly 29, 2025 | msn.comHC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 15, 2025 | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)July 14, 2025 | globenewswire.comSee More Headlines VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma PLC American Depositary Share's stock was trading at $46.44 on January 1st, 2025. Since then, VRNA shares have increased by 127.8% and is now trading at $105.7840. How were Verona Pharma PLC American Depositary Share's earnings last quarter? Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) posted its quarterly earnings data on Wednesday, August, 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. The company had revenue of $103.14 million for the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative trailing twelve-month return on equity of 21.12% and a negative net margin of 36.62%. When did Verona Pharma PLC American Depositary Share IPO? Verona Pharma PLC American Depositary Share (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma PLC American Depositary Share's major shareholders? Top institutional shareholders of Verona Pharma PLC American Depositary Share include Perceptive Advisors LLC (6.47%), Frazier Life Sciences Management L.P. (3.98%), Eventide Asset Management LLC (3.19%) and Hood River Capital Management LLC (1.84%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Andrew Fisher, Martin Edwards, Vikas Sinha, Mahendra Shah, Lisa Deschamps, Kenneth Cunningham, James Aloysius Brady and Michael Austwick. View institutional ownership trends. How do I buy shares of Verona Pharma PLC American Depositary Share? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verona Pharma PLC American Depositary Share own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma PLC American Depositary Share investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2025Today8/28/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Verona Pharma PLC American Depositary Share$109.00 High Price Target$170.00 Low Price Target$57.00 Potential Upside/Downside+3.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$173.42 million Net Margins-36.62% Pretax Margin-32.91% Return on Equity-21.12% Return on Assets-9.07% Debt Debt-to-Equity Ratio0.87 Current Ratio10.71 Quick Ratio10.54 Sales & Book Value Annual Sales$42.28 million Price / Sales216.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.22 per share Price / Book32.85Miscellaneous Outstanding Shares86,500,000Free Float82,344,000Market Cap$9.15 billion OptionableOptionable Beta0.12 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:VRNA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma PLC American Depositary Share Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma PLC American Depositary Share With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.